Use the hyperlinks, where available to access additional clinical trial information.
Frailty-stratified, randomised controlled Bayesian adaptive trial of bortezomib versus lenalidomide in transplant-ineligible myeloma (TI-NDMM)
Australasian Leukaemia and Lymphoma Group (ALLG)
Other Non-Commercial Sponsor
Medical Research Future Fund
Eligible patients will be randomised to receive one of the following treatment combinations:
(1) Velcade, Lenalidomide and Dexamethasone OR
(2) Velcade and Dexamethasone OR
(3) Lenalidomide and Dexamethasone.
All patients enrolled in the trial will continue to receive treatment until disease progression, unacceptable toxicity or withdrawal of consent.